Chronic Myeloid Leukemia — An Interview with Prof Andreas Hochhaus

Featuring an interview with Prof Andreas Hochhaus, including the following topics:

Biology of chronic myeloid leukemia (CML) and rationale for current therapeutic approaches; importance of cytogenetic testing (0:00)
Mechanistic differences among first-generation tyrosine kinase inhibitors (TKIs), second-generation TKIs and asciminib (6:09)
Potential mechanisms of adverse events documented with TKIs (10:23)
Recent survey of patients with CML regarding goals of therapy and clinical implications; considerations for discontinuation of therapy (16:23)
Comparative tolerability of asciminib and other agents used to manage CML; promoting adherence to treatment plans for patients (27:14)
Comparative efficacy of asciminib and other agents used to treat CML (40:01)
Potential areas for improvement in community oncology practice patterns; family planning in the context of CML treatment (43:53)
Practical care strategies for CML patients; future developments (52:32)